BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 2117516)

  • 1. Ovarian function during use of a levonorgestrel-releasing IUD.
    Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
    Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian function after seven years' use of a levonorgestrel IUD.
    Barbosa I; Olsson SE; Odlind V; Goncalves T; Coutinho E
    Adv Contracept; 1995 Jun; 11(2):85-95. PubMed ID: 7491859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability of an experimental intracervical device: results of a study controlling for selection bias.
    Shain RN; Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T; Holden AE; Rosenthal M
    Contraception; 1989 Jan; 39(1):73-84. PubMed ID: 2491982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
    Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
    Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of various IUDs on the composition of cervical mucus.
    Jonsson B; Landgren BM; Eneroth P
    Contraception; 1991 May; 43(5):447-58. PubMed ID: 1914458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
    Suvisaari J; Lähteenmäki P
    Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
    Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
    Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
    Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
    Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.
    Nilsson CG; Lähteenmäki P; Luukkainen T
    Contraception; 1980 Mar; 21(3):225-33. PubMed ID: 6771090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
    Niaraki MA; Moghissi KS; Borin K
    Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T; Toivonen J
    Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five years' experience with levonorgestrel-releasing IUDs.
    Luukkainen T; Allonen H; Haukkamaa M; Lähteenmäki P; Nilsson CG; Toivonen J
    Contraception; 1986 Feb; 33(2):139-48. PubMed ID: 3084167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
    Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1989 Feb; 39(2):195-204. PubMed ID: 2495893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early chorionic activity in women bearing inert IUD, copper IUD and levonorgestrel-releasing IUD.
    Videla-Rivero L; Etchepareborda JJ; Kesseru E
    Contraception; 1987 Aug; 36(2):217-26. PubMed ID: 3123135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.